Appetite suppressant drugs as inhibitors of human cytochromes P450: In vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine

Journal of Clinical Psychopharmacology

Volumn 18, Issue 4, 1998, Pages 338-341

  Von Moltke, Lisa L ^a   Greenblatt, David J ^a   Ciraulo, Domenic A ^a,b   Grassi, Jeffrey M ^a   Granda, Brian W ^a   Duan, Su Xiang ^a   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; ANOREXIGENIC AGENT; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DEXFENFLURAMINE; DEXTRORPHAN; DIETHYLDITHIOCARBAMIC ACID; ENZYME INHIBITOR; FENFLURAMINE; FLUOXETINE; KETOCONAZOLE; MIDAZOLAM; NORFLUOXETINE; PHENACETIN; PHENTERMINE; QUINIDINE; SULFAPHENAZOLE; TOLBUTAMIDE;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

APPETITE DEPRESSANTS; CULTURE TECHNIQUES; CYTOCHROME P-450 CYP2D6; FENFLURAMINE; HUMANS; MICROSOMES, LIVER; PHENTERMINE;

EID: 0031927911     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199808000-00015     Document Type: Article

References (24)

1. Weiser M, Frishman WH, Michaelson MD, Abdeen MA. The pharmacologic approach to the treatment of obesity. J Clin Pharmacol 1997;37:453-73.
2. McTavish D, Heel RC. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992;43:713-33.
3. Dvorak R, Starling RD, Callés-Escandon J, Sims EAH, Poehlman ET. Drug therapy for obesity in the elderly. Drugs Aging 1997; 11:338-51.
4. Bever KA, Perry PJ. Dexfenfluramine hydrochloride: an anorexigenic agent. Am J Health Syst Pharm 1997;54:2059-72.
5. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Beguad B. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-16.
6. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337: 581-8.
7. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268: 1278-83.
8. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
9. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JSM, Shader RI. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology (Berl) 1996;128:398-407.
10. Miners JO, Birkett DJ. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol 1996; 272:139-45.
11. Ho JW, Moody DE. Determination of tolbutamide hydroxylation in rat liver microsomes by high-performance liquid chromatography: effect of psychoactive drugs on in vitro activity. Life Sci 1992;52:21-8.
12. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6, and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 1997;18:227-40.
13. Court MH, von Moltke LL, Shader RI, Greenblatt DJ. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 1997; 18:213-26.
14. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-91.
15. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998;38:112-21.
16. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
17. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29[supp 1]:33-43.
18. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996;16:267-72.
19. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1996;16:273-85, 345-55.
20. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-22.
21. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions - an update. J Clin Psychopharmacol 1996;16:197-201.
22. Greenblatt DJ, von Moltke LL. Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes. In: W. Hori, ed. Drug-drug interactions: analyzing in vitro-in vivo correlations. Southboro, MA: International Business Communications, 1997:2.2.1-2.2.28.
23. Fogelson DL. Fenfluramine and the cytochrome P450 system. Am J Psychiatry 1997;154:436-7.
24. Price LH, Charney DS, Delgado PL, Heninger GR. Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol 1990;10:312-7.